Adimmune Corp
Albert Yueh-Peng Hung is a seasoned professional in the biotechnology and pharmaceutical industries, currently serving as Vice President of Business and Deputy Chief Operating Officer at Adimmune Corp since March 2016, where involvement in COVID-19 vaccine development and the management of various strategic projects has been pivotal. Previously, roles included Director of New Business Development at Animmune and President of Reber Genetics, focusing on innovative biologicals and swine-subunit vaccines across Asia and Russia. With extensive experience in business development, operational management, and team leadership, Albert's educational background includes a Master's Degree in Veterinary Preventive Medicine and a Bachelor's Degree in Veterinary Medicine from National Taiwan University.
This person is not in any teams
This person is not in any offices
Adimmune Corp
ADIMMUNE CORPORATION is a Taiwan-based company principally engaged in the research and development, processing, manufacture and trading of influenza vaccine products and non-flu vaccine products. The Company's products include Japanese encephalitis vaccines, tetanus vaccines, influenza vaccines, H1N1 influenza vaccines and tuberculin. The vaccine products are applied in the prevention of various infectious viruses. The tuberculin is applied in tuberculin purified protein derivative (PPD) test. The Company distributes its products within domestic market and to overseas markets, including other markets in Asia, Europe and Africa.